Secondary Packaging & Labelling
Experts in packaging and labelling patient kits for all drug therapies
Experts in packaging and labelling patient kits for all drug therapies
There are many challenges standing in the way of realising an effective and efficient clinical packaging and labelling operation.
Although vital, clinical supply is often an unseen timeline factor. Small and varied batch sizes can make it difficult to predict patient need. And changes to study size, scope and direction can compromise efficiency.
To help you overcome these and other nuanced challenges, and promote enhanced program performance, we’ve spent over a quarter of a century finetuning our secondary clinical packaging solutions to offer expert advice, pack design, packaging strategy and multilingual-labelled supplies.
Extensive global production capacity
We know that clinical supplies packaging and labelling is a critical step in the supply chain, which is why we’ve established a huge global production capacity, driven by semi and fully automated technology, to boost accuracy and reduce time and cost. It’s why we invest in continuous improvement; providing you with high levels of service, underpinned by our superior project management and technical knowledge. It’s why we offer in-house production of labels, randomisation lists, label translations, code break envelopes, scratch off panels and so much more.
It’s why, whatever your needs – if you’re looking for solutions to deliver successful labelling campaigns for vials, syringes or ampoules, round or square bottles, blisters, wallets or cartons, patches, or pouches – we have the expertise and superior capability to match it.
Enhanced label approval solutions
The increasing globalisation of clinical trials is making clinical labelling a more critical element of your operation than ever before. You must keep pace with the rapidly evolving regulatory landscape. You must understand the country specific nuances that will influence your labelling strategy. And you must develop robust processes that make all this possible.
Achieving this with in-house resource alone can be difficult and risk intensive. That’s why we’ve developed our enhanced label approval solution that takes care of all aspects of the process from protocol to print.
Why choose Almac?
We’re experts in packaging patient kits and clinical labelling across small molecule, biologics and hard to handle supplies, including controlled drug packs, potents, and biosimilars.
We’re also the most experienced provider of secondary packaging solutions in the industry, with proven experience in developing thousands of protocols for all types of studies including open label, randomised and cross-over studies.
This means that when you partner with us, you receive the most compliant and effective packaging design for your study, along with access to limitless expertise and pioneering services, including fully automated labelling and automated packaging technology.
When it comes to labelling, our dedicated project management teams, supported by our own centralised Label Approval System and approved phrase library capabilities, deliver seamless processes that help minimise your timelines and create more patient centric supply chains.
Because we care about improving the efficiency and flexibility of your packaging operations, we offer global resource to suit your trial needs. We offer kit and patient pack design and expertise to minimise waste and improve your supply strategy. We utilise enhanced label generation and production processes to reduce cycle times and improve compliance. And through integrating packaging supply with our supply chain management services, we offer forecasting, planning and a holistic view of the full supply chain, which empowers you to plan entire production campaigns in advance.
Supplying with care…
Global Manufacturing & labelling suites
Dan Megill
Director of Operations
“Clinical packaging has transformed massively in the 25 years that I’ve been working in the drug development sector.
The advancement of biologics and cell & gene therapies have been a major catalyst for innovation in that time – in terms of materials, processes, and production strategies.
Supplying with care means embracing changes that disrupt the status quo and being quick and agile in developing effective solutions for clients so they can continue to best support their patients and bring new drugs to market successfully.”
